Back to Search Start Over

Phase I evaluation of AT-125 single dose every three weeks.

Authors :
Taylor S
Belt RJ
Joseph U
Haas CD
Hoogstraten B
Source :
Investigational new drugs [Invest New Drugs] 1984; Vol. 2 (3), pp. 311-4.
Publication Year :
1984

Abstract

A Phase I trial of AT-125 was completed for the bolus dose every three week schedule. Dose limiting toxicity was primarily central nervous system (CNS) in the form of ataxia, confusion, hallucinations and dysarthria. Although this was most severe at doses of 150 mg/m2, lesser symptoms were reported at all dose levels. Nausea and vomiting were moderate to severe at higher doses. Myelosuppression did not occur. This schedule is not recommended for Phase II studies until methods are developed to reduce drug-related CNS toxicity.

Details

Language :
English
ISSN :
0167-6997
Volume :
2
Issue :
3
Database :
MEDLINE
Journal :
Investigational new drugs
Publication Type :
Academic Journal
Accession number :
6511237
Full Text :
https://doi.org/10.1007/BF00175382